10/511886 DT01 Rec'd PCT/7 19 OCT 20014

In the Claims:

1. (original) Compound in the form of a pure optical isomer (1R,2R) or (1S,2S) or in the form of a threo diastereoisomer, corresponding to general formula (I)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ R_{2} & & & \\ \hline \end{array}$$

in which A represents

either a group of general formula N-R₁ in which R₁ represents either a hydrogen atom, or a linear or branched (C₁-C₇)alkyl group optionally substituted with one or more fluorine atoms, or a (C₄-C₇)cycloalkyl group, or a (C₃-C₇)cycloalkyl(C₁-C₃)alkyl group, or a phenyl(C₁-C₃)alkyl group optionally substituted with one or two hydroxyl or methoxy groups, or a (C₂-C₄)alkenyl group, or a (C₂-C₄)alkynyl group, or a group of general formula N⁺(O⁻)R₁ in which R₁ is as defined above, or alternatively a group of general formula N⁺(R')R₁ in which R' represents a linear or

X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, linear or branched (C_1-C_4) alkyl and (C_1-C_4) alkoxy groups,

 R_2 represents either a hydrogen atom, or one or more substituents chosen from halogen atoms and trifluoromethyl, (C_1-C_4) alkyl or (C_1-C_4) alkoxy groups, or amino groups of general formula NR_3R_4 in which R_3 and R_4 each represent, independently of each other, a hydrogen atom or a (C_1-C_4) alkyl group, or form with the nitrogen atom carrying them a pyrrolidine, piperidine or morpholine ring, or a phenyl group optionally substituted with an atom or a group as defined for the symbol X above,

in the form of a free base or of an addition salt with an acid.

branched (C_1-C_7) alkyl group and R_1 is as defined above,

2. (currently amended) Compound, A compound according to Claim 1, characterized in that wherein it has the configuration (1S,2S) and in that R_2 represents one or more halogen atoms or trifluoromethyl groups.

3. (currently amended) Compound, A compound according to Claim 1, characterized in that wherein it has the configuration (1R,2R) and in that R_2 represents a halogen atom and an amino group of general formula NR_3R_4 as defined in Claim 1.

4. (cancelled)

- 5. (currently amended) A Pharmaceutical composition, characterized in that it contains comprising a compound according to Claim 1 one of Claims 1 to 3, combined with an excipient.
- 6. (new) 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide according to claim 1.
- 7. (new) 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride 1:1 according to claim 6.
- 8. (new) A pharmaceutical composition comprising a compound according to Claim 2 combined with an excipient.
- 9. (new) A pharmaceutical composition comprising a compound according to Claim 3 combined with an excipient.
- 10. (new) A pharmaceutical composition comprising a compound according to Claim 6 combined with an excipient.
- 11. (new) A pharmaceutical composition comprising a compound according to Claim 7 combined with an excipient.
- 12. (new) A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

- 13. (new) A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.
- 14. (new) A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.
- 15. (new) A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 6.
- 16. (new) A method for the treatment of disorders in which glycine transporters are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 7.